|Bid||27.90 x 800|
|Ask||28.00 x 800|
|Day's Range||27.60 - 28.42|
|52 Week Range||16.55 - 36.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.13|
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acorda ...
Acorda Therapeutics, Inc. (ACOR) today announced that Rick Batycky, Ph.D., Chief Technology Officer, will be leaving Acorda as of August 20, 2018 to take a position as the CEO of a private, venture-backed biotechnology company. David Lawrence, Acorda’s Chief of Business Operations, will assume responsibility for the company’s Chelsea, MA manufacturing facility, which produces INBRIJA™ (levodopa inhalation powder), as well as for the external manufacturing of AMPYRA® (dalfampridine). Burkhard Blank, M.D., Acorda’s Chief Medical Officer, will assume responsibility for Acorda’s Pharmaceutical Development and Technical Operations teams.
Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.
Acorda (ACOR) delivered earnings and revenue surprises of 86.67% and 19.10%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Acorda Therapeutics, Inc. (NASDAQ: ACOR ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:30 AM Eastern ...
The Ardsley, New York-based company said it had net income of 98 cents per share. Earnings, adjusted for one-time gains and costs, came to $1.40 per share. The results exceeded Wall Street expectations. ...
ARDSLEY, N.Y.-- -- INBRIJA™ NDA under FDA review; PDUFA date October 5, 2018 AMPYRA® 2Q 2018 net sales of $150.3 million; reiterating 2018 guidance of $330-$350 million Awaiting AMPYRA patent decision from U.S. Court of Appeals Acorda Therapeutics, Inc. provided a financial and pipeline update for the quarter ended June 30, 2018. “Our outstanding quarter reflected the continued excellence of our specialty ...
Shares of Acorda Therapeutics Inc. (acor) tumbled more than 17% Wednesday, after the company said an appeals court has denied its motion on patents for its multiple sclerosis treatment Ampyra. The company had filed for an injunction pending a decision in its appeal of a U.S. District Court decision from 20717 in patent litigation with generic drug makers. "If the Court of Appeals does not overturn the District Court's decision by July 30, 2018, multiple generic drug manufacturers may decide to launch at-risk generic versions of Ampyra," the company said in a regulatory filing.
Cardinal Health (CAH) is likely to witness solid growth in the core Pharmaceutical segment in Q4 results. However, lackluster performance in the Cordis unit is likely to mar prospects.
Acorda Therapeutics, Inc. (ACOR) will host a conference call and webcast to report its second quarter 2018 update and financial results on Thursday, August 2 at 8:30 a.m. ET. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.
Biotech stocks came under pressure earlier in the week, weighed down by negative trial results, mixed FDA verdicts and overall pessimistic broader market sentiment, but recovered in the last two sessions. ...
Acorda Therapeutics, Inc. (ACOR) will present four encore INBRIJA posters at the upcoming 2nd Pan American Parkinson’s Disease and Movement Disorders Congress taking place June 22-24, 2018 in Miami, Florida. INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen.
NEW YORK, NY / ACCESSWIRE / June 11, 2018 / Acorda Therapeutics was seeing big gains on Friday after Wall Street learned that the company's lawyers had try to save previously invalidated patents for its ...